This measure evaluates the number of inappropriately utilized Mohs surgeries to treat pathologically-proven primary squamous cell carcinomas in situ (SCCis) of any size on the trunk and keratoacanthoma (SCC-KA) on the trunk that are 1 cm or smaller in immunocompetent patients. The assessment of inappropriate use of Mohs surgery will help to improve compliance with AUC and should result in healthcare savings. (Inverse Measure: Low count indicates better performance) The percentage of immune‐competent patients with pathologically‐proven primary squamous carcinoma in situ (SCCis) lesions of any size on the trunk (chest, back, abdomen) or keratoacanthoma type squamous cell carcinoma (SCC‐KA) lesions 1 cm or smaller on the trunk (chest, back, abdomen) who are treated with Mohs surgery.